Final APPRAISE-al: Trial Report Argues Against Anticoagulant/Antiplatelet Combos In ACS
NEJM article points to much higher bleeding with no compensatory efficacy in failed APPRAISE-2 add-on trial with apixaban.
NEJM article points to much higher bleeding with no compensatory efficacy in failed APPRAISE-2 add-on trial with apixaban.